Vaccine Code Set Update Publication Date: December 21, 2023
The individual filenames included in this distribution contain the publication date (20231221)
Release Notes: This release includes updates for all vaccine codes and maps but does not include codes for Vaccine Information Statements (VIS).
General note regarding this release: Codes with “Last Update” dates after November 06, 2023, and before December 21, 2023, reflect the changes and additions in this release. This release includes the following code set updates:
- New pentavalent meningococcal vaccine (PENBRAYA) kit NDCs
- New Pfizer COMIRNATY COVID-19 no freeze presentation NDCs for ages 12 and older
- New Chikungunya vaccine codes
- Correction to CVX note field for CVX code 208
- Other Changes
Vaccine Code Set Updates – Details
1. New pentavalent meningococcal vaccine (PENBRAYA) kit NDCs
NDCs and CPT are now added to complete the crosswalk for the new pentavalent Meningococcal Groups A, B, C, W, and Y vaccine (PENBRAYA). This Pfizer vaccine is packaged in a kit with two separate antigen unit of use NDCs to be reconstituted; Lyophilized MenACWY and a separate MenB recombinant component. A third kit NDC for an adapter is not included in the code sets.
CVX code 316 shown below is now also associated to CPT code 90623, “Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use”.
Proprietary Name | CVX | CVX Description | Manufacturer | MVX | Unit of Sale NDC11 (KITS) | Each KIT Contains 2 Unit of Use NDCs |
|---|
PENBRAYA | 316 | meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | Pfizer Laboratories | PFR | 00069-0600-01 | CARTON, 1 KIT | 00069-0332-01 | MenB recombinant component for reconstitution with MenACWY, 0.5 mL |
|---|
00069-0600-05 | CARTON, 5 KITS | 00069-0271-01 | MenACWY lyophilized component for reconstitution with MenB, 0.5 mL |
|---|
00069-0600-10 | CARTON, 10 KITS |
|---|
2. New Pfizer COMIRNATY COVID-19 no freeze presentation NDCs for ages 12 and older
Pfizer has introduced a new no freeze formulation for their COMIRNATY product. New NDCs have been added to the code set. This new pre-filled glass syringe presentation is never frozen and has a longer refrigeration shelf life. The frozen product is still available in two product presentations, a plastic syringe, and a vial. The new NDCs are clinically the same as the existing formulation for this age cohort and thus share the same CVX code and CPT code as the frozen product.
In addition to the NDCs cited below, the outer pack form and use unit pack form fields for the frozen syringe product have been updated to add the word “plastic” to differentiate the frozen syringe from the new glass syringe of the no-freeze presentation.
- The NDC pair with syringe description change are: UoS NDC11 00069-2392-10 | UoU NDC11 00069-2392-01
CVX | CVX Description | MVX | Sale Proprietary Name | Sale NDC10
NDC11 | Use NDC10
NDC11 | CPT | CPT Description |
|---|
309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | PFR | COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula), no freeze formulation | 0069-2377-10 00069-2377-10 CARTON, 10 PRE-FILLED GLASS SYRINGES | 0069-2377-01 00069-2377-01 GLASS SYRINGE, SINGLE-DOSE (DO NOT FREEZE) | 91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
|---|
3. New Chikungunya vaccine codes
New codes have been added for an FDA approved Valneva Chikungunya vaccine product (IXCHIQ). At this time, there are no NDCs listed. A new CVX code has been added and linked to a new Vaccine Group, “Chikungunya”. In addition, a new Product table entry for the tradename has been added and associated to the Valneva MVX. The CVX code has also been mapped to a CPT code.
CVX | CVX Description | MVX | Manufacturer | Proprietary Name | CPT | CPT Description |
|---|
317 | Chikungunya, live attenuated vaccine, 0.5 mL, preservative free | VAL | Valneva | IXCHIQ | 90589 | Chikungunya virus vaccine, live attenuated, for intramuscular use |
|---|
4. Correction to CVX Note field for CVX code 208
CVX code 208, “SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose” was updated to correct the note field text. The note now reads “Original monovalent Pfizer adult vaccine (12+ yrs). FDA rescinded all doses for US use 4/18/2023. Continue to use to record historic US Pfizer vaccines and non-US vaccines administered (includes tradename Comirnaty)”.
5. Other Changes
In addition to the code updates cited above, several Unit of Use and Unit of Sale NDCs in the vaccine code set show changes in December to their date of last update. These are due to minor changes on the FDA files that are not reflected in the files CDC publishes, but do update the dates in the CDC code set database.
